Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Slamon on the Use of Trastuzumab and Bevacizumab Biosimilars in Breast Cancer

April 25th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.

Everolimus Shows Efficacy in Combating Endocrine Resistance in Breast Cancer

April 25th 2018

Everolimus demonstrated strong potential as an effective tool for overcoming endocrine resistance in postmenopausal women with ER-positive, HER2-negative metastatic breast cancer resistant to AI therapy.

Expert Highlights Incorporation of Neoadjuvant Endocrine Therapy Into ER+ Breast Cancer

April 25th 2018

Hung T. Khong, MD, discusses the benefits of neoadjuvant endocrine therapy and addresses the use of adjuvant endocrine therapy in ER-positive breast cancer.

Immunotherapy's Role in TNBC May Be in Combination

April 24th 2018

Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.

Dr. Callahan on Endocrine Therapy in Patients With ER-Positive Breast Cancer

April 24th 2018

Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.

Dr. Master on the Relationship Between Diet and Breast Cancer Recurrence

April 22nd 2018

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the WINS and WHEL trials in patients with breast cancer.

Dr. DiNome on Surgical Approaches in Patients With Breast Cancer

April 22nd 2018

Maggie DiNome, MD, associate professor of surgery, University of California, Los Angeles Medical Center, discusses the evolution of surgical approaches in patients with breast cancer.

Role of PARP Inhibitors in Breast Cancer Continues to Be Refined

April 20th 2018

Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.

Hint of Survival Benefit With Olaparib in HER2-Negative/BRCA-Positive Metastatic Breast Cancer

April 16th 2018

Women with HER2-negative metastatic breast cancer associated with a germline BRCA mutation may have a slight survival advantage with a PARP inhibitor instead of chemotherapy.

Updated Breast Cancer Guidelines Help Evolve Radiation Decisions

April 13th 2018

Laura M. Freedman, MD, discusses the impact of the updated NCCN guidelines on clinical applications of radiation therapy in patients with breast cancer.

Adjuvant Setting in ER-Positive Breast Cancer Undergoing Transformation

April 13th 2018

Ruta D. Rao, MD, elaborates on the findings of the ABCSG-16, SOFT, and TEXT clinical trials and how they have shaped adjuvant treatment for ER-positive breast cancer.

Dr. Blackwell on the Treatment of Young Women With Breast Cancer

April 12th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the treatment of young women with breast cancer.

Dr. Valdes-Albini on the FDA Approval of Adjuvant Pertuzumab in HER2+ Breast Cancer

April 12th 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Chagpar on Surgery of the Primary Tumor in Metastatic Breast Cancer

April 12th 2018

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses surgery of the primary tumor in the metastatic setting of breast cancer.

Dr. Mamounas on Neoadjuvant Chemotherapy for Breast Cancer

April 12th 2018

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the management of neoadjuvant chemotherapy for patients with breast cancer.

Dr. Mahtani on Side Effects of Ovarian Suppression in Breast Cancer

April 9th 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Treatments Emerging to Combat Endocrine Resistance in ER+ Breast Cancer

April 6th 2018

Heather Han, MD, discusses emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.

Distinctive Features of Male Breast Cancer Identified

April 5th 2018

An analysis of clinical characteristics, gene expression, and 21-gene Breast Recurrence Score results identified distinctive biologic features of breast cancer in men.

Dr. Domchek Discusses Areas of Investigation in Breast Cancer

April 4th 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses areas of investigation in breast cancer.

Excitement Grows About PARP Inhibitors in BRCA-Mutated TNBC

April 4th 2018

A panel of experts discusses the role of BRCA1/2 mutation testing and how and when to incorporate PARP inhibitors into the care of patients with BRCA-positive TNBC.